Journals / MN Kardiyoloji / 2003 / Cilt: 10 - Sayı: 3

A case of primary pulmonary hypertension and severe heart failure developing after pregnancy treated with inhaled iloprost

Gebelik sonrası inhale iloprost ile tedavi edilen primer pulmoner hipertansiyon olgusu

Pages
213–216
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Altough it has been shovvn that calcium channel blocking agents and anticoagulants increase survival, this benefit can be observed in up to 25 % of cases. in recent studies, inhalational administration of iloprost, a prostacycline analoque, is shovvn to be considerably effective in severe PPH and could be an alternative to continuous intravenous iloprost administration. in this article, we report the efficacy of inhaled iloprost in a young female vvho was diagnosed with PPH before pregnancy and readmitted postpartum with high mortality New York Heart Association class- IV heart failure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Primary pulmonary hypertension (PPH) is a progressive disease of unknovvn etiology with a mean survival of less than 3 years after diagnosis.
📊
Key Findings & Data:Death usually follovvs a significant increase in pulmonary arterial pressure and consequently reduced cardiac output due to right heart failure.
💡
Conclusion & Impact:Altough it has been shovvn that calcium channel blocking agents and anticoagulants increase survival, this benefit can be observed in up to 25 % of cases. in recent studies, inhalational administration of iloprost, a prostacycline analoque, is shovvn to be considerably effective in severe PPH and could be an alternative to continuous intravenous iloprost administration. in this article, we report the efficacy of inhaled iloprost in a young female vvho was diagnosed with PPH before pregnancy and readmitted postpartum with high mortality New York Heart Association class- IV heart failure.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Erişkin · İloprost · Hipertansiyon

Abstract

Primary pulmonary hypertension (PPH) is a progressive disease of unknovvn etiology with a mean survival of less than 3 years after diagnosis. Death usually follovvs a significant increase in pulmonary arterial pressure and consequently reduced cardiac output due to right heart failure. Altough it has been shovvn that calcium channel blocking agents and anticoagulants increase survival, this benefit can be observed in up to 25 % of cases. in recent studies, inhalational administration of iloprost, a prostacycline analoque, is shovvn to be considerably effective in severe PPH and could be an alternative to continuous intravenous iloprost administration. in this article, we report the efficacy of inhaled iloprost in a young female vvho was diagnosed with PPH before pregnancy and readmitted postpartum with high mortality New York Heart Association class- IV heart failure.

Özet

Primer pulmoner hipertansiyon, sebebi bilinmeyen ve tanı konulduktan itibaren ortalama yaşam süresi 3 yıldan daha az olan progresif bir hastalıktır. Ölüm, genellikle pulmoner arter basıncında belirgin düzeyde yükselme ve sonunda gelişen sağ kalp yetmezliğine bağlı azalan kardiyak output nedeniyledir. Kalsiyum kanal blokerleri ve antikoagülan tedavinin yaşam süresini arttırdığı gösterilse de, hastaların ancak %25'inde bu fayda gözlenebilmektedir. Son zamanlarda yapılan çalışmalarda, bir prostasiklin analoğu olan iloprost'un inhalasyonla tatbikinin, ciddi pulmoner hipertansiyon vakalarında oldukça etkili olduğu ve sürekli intravenöz iloprost uygulamasına alternatif olabileceği ifade edilmiştir. Bu yazımızda, gebelik öncesi primer pulmoner hipertansiyon tanısıyla takip edilen ve postpartum dönemde New York Kalp Cemiyetinin fonksiyonel sınıflamasına göre yüksek mortaliteye sahip sınıf - VI kalp yetmezliği gelişen bir hastada, inhale iloprost tedavisinin etkinliği sunulmaktadır.

🔖

Cite This Article

AMASYALI, B., KÖSE, S., KURŞAKLIOĞLU, H., KABUL, K., IŞIK, E., DEMİRTAŞ, E. (2003). A case of primary pulmonary hypertension and severe heart failure developing after pregnancy treated with inhaled iloprost. MN Kardiyoloji, Cilt: 10 - Sayı: 3, 213–216. https://ajindex.com/articles/297816

References (11)

  1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-23.
  2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
  3. Fuster V, Steele PM, Edwards WD, et al. Primary pulmoner hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-7.
  4. Petkov V, Ziesche R, Mosgoeller W, et al. Aerosolised ilo­ prost improves pulmonary haemodynamics in patients with pri­ mary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56:734-6.
  5. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Woll- bruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension with aerosoli- zation of iloprost. Intensive Care Med 1998; 24:631-4.
  6. Olschewski H, Simonneau G, Galie N, etal. Inhaled Iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-9.
  7. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled Ilop­ rost to treat severe pulmonary hypertension. Ann Intern Med 2000; 132:435-43.
  8. Barst RJ, Rubin LJ, Long WA, et al. A comparison of contino- us intravenous epoprostenol with conventional therapy for pri­ mary pulmonary hypertension. N Engl J Med 1996; 334:296-301.
  9. Warren JB, Higenbottam T. Caution with use of inhaled nitric oxide. Lancet 1996; 348: 629-30.
  10. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35:176-82.
  11. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grim­ minger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-4.